Last reviewed · How we verify
Adebrelimab combined with SOX regimen
Adebrelimab combined with SOX regimen is a PD-L1 inhibitor Small molecule drug developed by Yang Jianjun, PhD. It is currently FDA-approved for Gastric cancer or gastroesophageal junction cancer (in combination with SOX chemotherapy).
Adebrelimab is a PD-L1 inhibitor that blocks the interaction between PD-L1 and PD-1/PD-L2, restoring anti-tumor immune responses, combined with SOX chemotherapy (S-1 and oxaliplatin) for enhanced cytotoxic and immunological effects.
Adebrelimab is a PD-L1 inhibitor that blocks the interaction between PD-L1 and PD-1/PD-L2, restoring anti-tumor immune responses, combined with SOX chemotherapy (S-1 and oxaliplatin) for enhanced cytotoxic and immunological effects. Used for Gastric cancer or gastroesophageal junction cancer (in combination with SOX chemotherapy).
At a glance
| Generic name | Adebrelimab combined with SOX regimen |
|---|---|
| Sponsor | Yang Jianjun, PhD |
| Drug class | PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Adebrelimab is a monoclonal antibody targeting programmed death ligand 1 (PD-L1), which when bound to PD-1 on T cells suppresses anti-tumor immunity. By blocking this interaction, adebrelimab releases the brakes on T cell activation, allowing enhanced tumor recognition and killing. The SOX regimen provides direct chemotherapy-induced cytotoxicity, and the combination leverages both chemotherapy and immunotherapy mechanisms.
Approved indications
- Gastric cancer or gastroesophageal junction cancer (in combination with SOX chemotherapy)
Common side effects
- Nausea and vomiting
- Diarrhea
- Fatigue
- Immune-related adverse events (pneumonitis, hepatitis, colitis)
- Myelosuppression
Key clinical trials
- Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer (PHASE3)
- Adebrelimab Combined With SOX Regimen in Preoperative Neoadjuvant Transformation Therapy for Locally Advanced Gastric Adenocarcinoma (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adebrelimab combined with SOX regimen CI brief — competitive landscape report
- Adebrelimab combined with SOX regimen updates RSS · CI watch RSS
- Yang Jianjun, PhD portfolio CI
Frequently asked questions about Adebrelimab combined with SOX regimen
What is Adebrelimab combined with SOX regimen?
How does Adebrelimab combined with SOX regimen work?
What is Adebrelimab combined with SOX regimen used for?
Who makes Adebrelimab combined with SOX regimen?
What drug class is Adebrelimab combined with SOX regimen in?
What development phase is Adebrelimab combined with SOX regimen in?
What are the side effects of Adebrelimab combined with SOX regimen?
What does Adebrelimab combined with SOX regimen target?
Related
- Drug class: All PD-L1 inhibitor drugs
- Target: All drugs targeting PD-L1
- Manufacturer: Yang Jianjun, PhD — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Gastric cancer or gastroesophageal junction cancer (in combination with SOX chemotherapy)
- Compare: Adebrelimab combined with SOX regimen vs similar drugs
- Pricing: Adebrelimab combined with SOX regimen cost, discount & access